CBD Oil Market

How big is CBD Oil Market in 2026?

Global CBD oil market size is projected to climb from USD 5.4 billion in 2025 to USD 6.1 billion in 2026, advancing at an anticipated 12.0% CAGR to reach a valuation of USD 18.9 billion by 2036.

Neurologists and hospital pharmacists increasingly rely on standardized oral cannabidiol drops for patients whose seizures do not respond to conventional medication, supported by a May 2026 meta-analysis of seven randomized trials covering 1,154 drug-resistant epilepsy patients in Therapeutics and Clinical Risk Management that showed a 0.72 pooled risk ratio for seizure reduction at 20 milligrams per kilogram daily [1]. Because insurer coverage and specialty pharmacy dispensing continue to widen on the back of these clinical results, FMI estimates that the global CBD oil market value will grow from USD 5.4 billion in 2025 to USD 6.1 billion in 2026 and reach USD 18.9 billion by 2036, progressing at an anticipated 12.0% CAGR to deliver USD 12.8 billion in absolute market growth. Industrial Hemp-Derived CBD Oil is projected to hold 68.7% of botanical source market value in 2026 as processors blend compliant extracts with carrier oils such as hemp seed oil for steady absorption. Even so, doctors still monitor liver enzymes closely when patients take cannabidiol together with valproate.

Key Market Trends & Insights

• By botanical source: Industrial Hemp-Derived CBD Oil is projected to capture 68.7% in 2026 because compliant Cannabis sativa cultivars below 0.3% delta-9-THC qualify for interstate bulk extraction.
• By spectrum profile: Full-Spectrum & Broad-Spectrum Distillate is estimated to command 71.3% in 2026 as formulators retain minor cannabigerol and beta-caryophyllene fractions for sublingual oil drops.
• By end-use vertical: Pharmaceuticals are expected to concentrate 42.3% in 2026 because insurer-reimbursed anticonvulsant oral solutions command high annual per-patient realization.
• By extraction technology: Supercritical CO2 Extraction is forecast to generate 44.7% in 2026 owing to tuneable pressure fractionation that eliminates residual hydrocarbon solvents.
• By distribution channel: Hospital & Retail Prescription Pharmacies are anticipated to account for 46.3% in 2026 through physician-supervised dispensing of standardized cannabinoid oils.

Regional Highlights

• Top national expansion: Brazil is projected to lead evaluated national markets at a 13.6% CAGR through 2036 under ANVISA Resolution RDC 327/2019 pharmacy dispensing and RDC 660/2022 patient import authorizations.
• Broader country progression: Australia is expected to expand at 13.2% CAGR ahead of Canada at 12.9% and Germany at 11.8%, while the USA (11.4%) and the UK (11.2%) are forecast to advance through pharmacy and wellness channels.

Market Size & Forecast

Table 1: Market Size and Forecast for the CBD Oil Market (USD billion and CAGR percentage), 2025 to 2036

Metric	Value
2025 Market Size	USD 5.4 billion
Estimated Market Size in 2026	USD 6.1 billion
Projected Market Size by 2036	USD 18.9 billion
CAGR, 2026 to 2036	12.0%
Added Revenue, 2026 to 2036	USD 12.8 billion

Larger outdoor floral hemp harvests and controlled indoor growing rooms have made raw cannabinoid supply far more predictable for medical and wellness oil refiners. In April 2026, the United States Department of Agriculture National Agricultural Statistics Service reported in its National Hemp Report that total U.S. industrial hemp production value reached USD 739 million for 2025 (up 64% from 2024), led by 33.2 million pounds of outdoor floral hemp harvested across 16,880 acres valued at USD 574 million [2]. On the back of this harvest recovery, refiners are upgrading cold-filtration and distillation lines used for botanical extracts so pharmacy and retail buyers receive consistent oil strength from batch to batch.

Biomass Extraction and Active Cannabinoid Sizing

Table 2: Biomass Extraction and Active Cannabinoid Sizing for the CBD Oil Market (USD billion and operational ranges), 2025 to 2036

Metric	2025	2026	2036
Market size (USD billion)	5.4	6.1	18.9
Processed floral hemp and cannabis biomass (thousand tonnes)	18.5 to 21.2	20.8 to 23.9	58.0 to 66.5
Refined CBD distillate and isolate output (tonnes)	920 to 1,060	1,040 to 1,195	2,950 to 3,380
Average realized oil value per kg active CBD (USD)	5,100 to 5,850	5,100 to 5,860	5,590 to 6,400

Operational note: Biomass and refined distillate ranges reflect dried floral material yielding 8.0% to 12.0% crude cannabidiol prior to winterization and short-path vacuum fractional distillation.

Oil processors carefully control heating times during decarboxylation so raw cannabidiolic acid converts into active cannabidiol without burning off delicate plant aromatics. Many contract formulators then blend purified distillates with medium-chain triglycerides to keep dropper dosing uniform and help the oil absorb smoothly under the tongue.

Per Capita & Pharmacy Dispensing Sizing

Table 3: Per Capita and Pharmacy Dispensing Indicators for the CBD Oil Market (USD), 2025 to 2036

Metric	2025	2026	2036
World population (billion)	8.2	8.3	9.0
Spend per 1,000 people (USD)	658.5	734.9	2,100.0
Annual spend per prescription epilepsy patient (USD)	28,500 to 34,200	29,200 to 35,000	33,500 to 39,800
GMP-certified extraction share of commercial volume (%)	54.0% to 58.0%	57.0% to 61.0%	76.0% to 81.0%

Table 4: Pharmacy & Extraction Facility Spending Indicators for the CBD Oil Market (USD and percentages), 2026

Metric	Value	Institutional Reference Basis
Market size, 2026	USD 6.1 billion	2026 global revenue baseline
Licensed cannabinoid extraction facilities worldwide	1,450 facilities	Global GMP and state-licensed processor registry
Pharmaceuticals vertical revenue, 2026	USD 2.6 billion	42.3% end-use vertical allocation
Hospital & retail prescription pharmacy revenue, 2026	USD 2.8 billion	46.3% distribution channel allocation

Because plain cannabidiol dissolves poorly in water and much of an oral dose is broken down by the liver before reaching the bloodstream, oil makers put heavy emphasis on carrier formulation. Contract softgel producers now pair self-emulsifying lipid systems with herbal supplements so patients absorb a more consistent share of each dose.

Analyst Perspective

"Commercial cannabinoid oil procurement is bifurcating between EU-GMP pharmaceutical oral solutions and COA-verified full-spectrum wellness tinctures. Processors that pair solventless supercritical CO2 extraction with lipid nano-emulsion carriers are expected to capture institutional pharmacy contracts across European and Australasian healthcare corridors."

- Nandini Roy Choudhury, Principal Consultant, Future Market Insights.

How is the CBD oil market segmented?

The CBD oil market is segmented by botanical source, spectrum profile, end-use vertical, extraction technology, and distribution channel. In 2026, Industrial Hemp-Derived CBD Oil is projected at 68.7%, Full-Spectrum & Broad-Spectrum Distillate at 71.3%, Pharmaceuticals at 42.3%, Supercritical CO2 Extraction at 44.7%, and Hospital & Retail Prescription Pharmacies at 46.3%.

By botanical source: Industrial Hemp-Derived CBD Oil, and Medical Cannabis-Derived CBD Oil.

By spectrum profile: Full-Spectrum & Broad-Spectrum Distillate, and 99%+ Pure Crystalline CBD Isolate in MCT Carrier Oil.

By end-use vertical: Pharmaceuticals, Nutraceutical Sublingual Tinctures & Softgels, and Topical Balms, Skincare & Functional Beverages.

By extraction technology: Supercritical CO2 Extraction, Cryogenic Ethanol Extraction, and Hydrocarbon & Lipid Infusion.

By distribution channel: Hospital & Retail Prescription Pharmacies, D2C E-Commerce & Specialty Wellness, and Licensed Medical Dispensaries.

Why does Industrial Hemp-Derived CBD Oil lead the botanical source category?

Industrial Hemp-Derived CBD Oil is projected to capture 68.7% of botanical source demand in 2026, supported by compliant cultivation.

Table 5: Botanical Source Share for the CBD Oil Market (percentage share), 2026

Botanical Source	Share (2026)
Industrial Hemp-Derived CBD Oil	68.7%
Medical Cannabis-Derived CBD Oil	31.3%*
Total	100.0%

*Note: Remaining botanical source category sums to 100.0% of 2026 global cannabinoid oil volume.

Table 6: Botanical Source Leadership and Market Growth for the CBD Oil Market (segment and CAGR percentage), 2026 to 2036

Metric	Value
Global CAGR (2026 to 2036)	12.0%
Leading Segment	Industrial Hemp-Derived CBD Oil

Extractor economics favor registered industrial hemp cultivars because outdoor floral harvests yield high cannabidiolic acid concentrations while keeping delta-9-tetrahydrocannabinol below statutory 0.2% to 0.3% dry-weight thresholds. Unlike indoor narcotic medical cannabis crops that require vault security and quota licensing, field-grown hemp biomass moves across commercial extraction hubs to feed botanical supplements and bulk distillate supply chains.

• Industrial Hemp-Derived CBD Oil is projected to secure 68.7% of botanical source revenue in 2026 by combining open-field biomass scalability with non-narcotic freight clearance.
• An August 2025 open-label clinical trial at McLean Hospital published in Biomedicines demonstrated that patients receiving 30 milligrams daily of hemp-derived full-spectrum sublingual CBD oil achieved significant anxiety reductions and cognitive improvements over six weeks [3].

Why does Full-Spectrum & Broad-Spectrum Distillate define the largest spectrum profile segment?

Full-Spectrum & Broad-Spectrum Distillate is estimated to secure 71.3% of the spectrum profile category in 2026, driven by terpene retention.

Whole-plant distillates keep minor cannabinoids like cannabigerol together with natural plant terpenes, which gives patients and wellness users a broader effect than single-molecule isolate powders. Processors use gentle wiped-film distillation and chromatography to strip out unwanted delta-9-THC before filling broad-spectrum oils into softgel capsules and measured dropper bottles.

• Full-Spectrum & Broad-Spectrum Distillate options are estimated to command 71.3% of the spectrum profile segment in 2026 as clinicians and wellness consumers favor multi-cannabinoid oil matrices.
• A January 2025 population pharmacokinetic study of 48 pediatric patients with developmental and epileptic encephalopathies published in Epilepsia confirmed that lipid meal co-administration increased oral cannabidiol peak plasma concentration by 41% and area under the curve by 45% across oil formulations [4].

What keeps Pharmaceuticals ahead by end-use vertical?

Pharmaceuticals are expected to command 42.3% of end-use vertical volume in 2026, reflecting reimbursed refractory epilepsy prescriptions.

Prescription oral solutions generate the largest share of industry market value because national health insurers reimburse daily weight-based dosing for severe childhood epilepsies such as Dravet and Lennox-Gastaut syndromes. Whilst everyday retail hemp drops face price competition on store shelves, GMP-certified cannabinoid medicines continue to gain ground with herbal medicinal products in hospital neurology and pain clinics.

• Pharmaceuticals are expected to hold 42.3% of end-use vertical market value in 2026 because chronic anticonvulsant regimens require continuous daily oil titration.
• Jazz Pharmaceuticals reported in February 2026 that full-year 2025 net product sales of its FDA-approved oral cannabidiol solution Epidiolex reached USD 1,059.2 million, representing 9% annual growth across more than 35 approved countries [5].

Why does Supercritical CO2 Extraction lead the extraction technology category?

Supercritical CO2 Extraction is forecast to generate 44.7% of extraction technology revenue in 2026, owing to solvent-free selectivity.

Pressurized carbon dioxide held above 31.1 degrees Celsius and 73.8 bar pulls active cannabinoids and fragrant terpenes out of hemp flowers without dragging along bitter green chlorophyll. Unlike butane or hexane methods that require heavy vacuum purging to clear solvent residues, closed-loop botanical CO2 extracts equipment produces clean oils ready for pharmacy compounding.

• Supercritical CO2 Extraction is forecast to account for 44.7% of extraction technology demand in 2026 as pharmacopeial purity audits penalize residual hydrocarbon solvents.
• A February 2025 process-engineering study from Ca' Foscari University of Venice published in ACS Agricultural Science & Technology validated a scaled supercritical CO2 extraction protocol at 250 bar and 40 degrees Celsius followed by C18 filtration that recovered over 99% pure CBD at 52% overall yield [6].

What gives Hospital & Retail Prescription Pharmacies the leading position in distribution channel?

Hospital & Retail Prescription Pharmacies are anticipated to account for 46.3% of distribution channel valuation in 2026, reinforced by pharmacist-supervised dispensing.

Licensed hospital and community pharmacies control patient access across Europe and Latin America as well as Australia because regulators classify medical cannabidiol oils as prescription-only preparations. Pharmacists guide dose adjustments and check for drug interactions with routine blood tests, whilst consumers seeking localized muscle comfort still buy over-the-counter topical pain relief balms at wellness shops.

• Hospital & Retail Prescription Pharmacies are anticipated to capture 46.3% of distribution channel revenue in 2026 because statutory reimbursement and magistral compounding require licensed pharmacy fulfillment.
• In August 2026, Jazz Pharmaceuticals reported that second-quarter 2026 Epidiolex net sales rose 16% year-over-year to USD 292.1 million following submission of a supplemental New Drug Application for a new oral cannabidiol capsule formulation [7].

What are the drivers, restraints, and opportunities in the CBD oil market?

In the CBD oil market, expanding prescription neurology coverage and pharmacy magistral access are projected to accelerate volume whereas hepatic CYP450 drug interactions restrain high-dose escalation and self-emulsifying nano-carriers create bioavailability opportunities.

• Driver: Positive phase-three clinical trials in treatment-resistant epilepsies and chronic pain bring standardized CBD oils onto insurer-reimbursed pharmacy formularies.
• Restraint: Extensive first-pass hepatic clearance (~6% oral bioavailability) and CYP3A4/CYP2C19 enzyme inhibition require clinical liver-function monitoring at therapeutic doses.
• Opportunity: Self-nanoemulsifying lipid carriers and freeze-dried cannabinoid powders triple oral absorption while keeping products stable at room temperature.

Growth Analysis and Future Potential: Qualitative Demand Catalysts

Hospital neurology departments and outpatient dermatology clinics are expanding cannabinoid oil prescribing as randomized clinical trials verify anti-inflammatory and anticonvulsant mechanisms across TRPV1 and GPR55 receptor pathways. In October 2025, a multi-center pharmacological review published in Acta Pharmaceutica Sinica B documented 484 registered clinical trials evaluating cannabidiol interventions (with 204 completed), confirming that microemulsion and hydrogel carriers suppress pro-inflammatory NF-kappaB signaling in chronic tissue inflammation [8]. Future Market Insights notes that clinical validation is shifting buyer demand toward pharmaceutical-grade oils and standardized skincare products backed by batch-specific certificates of analysis.

Risk Assessment of the CBD Oil Market: Pharmacokinetic and Regulatory Friction

Poor water solubility and uneven gut absorption together with liver enzyme interactions remain the main hurdles holding back higher-dose oral CBD oil regimens. In February 2026, a neurology review of 107 clinical and preclinical studies from the Polish Academy of Sciences in Pharmaceuticals noted that oral cannabidiol is heavily processed by CYP3A4 and CYP2C19 liver enzymes and can raise liver transaminases when taken with clobazam or valproate [9]. At the same time, slow Novel Food approvals in Europe and shifting state hemp rules in the United States make cross-border retail sales harder to manage.

Commercial Opportunity Analysis: Nano-Emulsion and Lyophilizate Engineering

Pharmaceutical contract development and manufacturing organizations are capturing premium formulation margins by engineering lipid nano-carriers that bypass hepatic first-pass degradation. Conventional sesame or coconut oil tinctures exhibit roughly 6% oral bioavailability under fasting conditions because 75% of absorbed cannabidiol is cleared during initial portal circulation. In October 2025, an evaluation of 58 formulation studies from Poznan University of Medical Sciences published in Pharmaceuticals demonstrated that self-nanoemulsifying drug delivery systems and nanostructured lipid carriers significantly elevate peak plasma concentration and area under the curve for lipophilic cannabidiol [10]. Suppliers offering water-dispersible nano-emulsions and enteric-coated lipid capsules are projected to win multi-year licensing agreements with beverage and specialty pharma brands.

CBD Oil Market by Country (2026 to 2036)

As per FMI, Brazil is projected to lead national CBD oil growth at a 13.6% CAGR through 2036, whereas the UK is forecast to progress at an 11.2% annual pace. How quickly each country expands depends on local THC limits and public health insurance coverage as well as how easily doctors can write special-access prescriptions.

Table 7: Country CAGR and Primary Growth Levers for the CBD Oil Market (CAGR percentage and operational drivers), 2026 to 2036

Country	CAGR (2026 to 2036)	Primary Growth Lever
Brazil	13.6%	ANVISA RDC 327/2019 pharmacy dispensing and SUS court-mandated public reimbursement expansion
Australia	13.2%	TGA Special Access Scheme and Authorised Prescriber Schedule 4 CBD oil pharmacy scripts
Canada	12.9%	Health Canada GMP export licensing and insured veterans medical cannabis oil coverage
Germany	11.8%	MedCanG non-narcotic e-prescription integration and statutory GKV pharmacy reimbursement
USA	11.4%	Wider Epidiolex neurology prescribing and USDA-certified organic full-spectrum hemp tincture demand
UK	11.2%	Specialist private clinic registry prescribing and FSA Novel Food Positive List reformulations

Source: Future Market Insights analysis

Brazil CBD Oil Market Outlook (2026 to 2036)

Unlike North American over-the-counter wellness markets, Brazil channels commercial cannabidiol oil demand exclusively through physician prescriptions under ANVISA Resolution RDC 327/2019 for domestic pharmacy dispensing and RDC 660/2022 for individual patient imports. A February 2025 regulatory quality audit from the University of Brasilia published in the Journal of Cannabis Research evaluated 105 commercial cannabidiol oils in Brazil and found that pharmacy-registered RDC 327 products achieved a median labeling compliance score of 53.50 versus 26.50 for imported RDC 660 oils [11]. Brazilian CBD oil market value is projected to expand at a leading 13.6% CAGR through 2036 as state Unified Health System (SUS) formularies broaden free epilepsy and autism oil coverage.

Key takeaway: In Brazil, ANVISA RDC 327/2019 pharmacy quality enforcement and state SUS court-approved reimbursement are projected to anchor rapid medical CBD oil adoption.

Australia CBD Oil Market Outlook (2026 to 2036)

Whereas European wellness retailers sell low-strength hemp drops without clinical supervision, Australia regulates medicinal cannabis oils through Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) and Authorised Prescriber physician pathways. According to the TGA Medicinal Cannabis Product List updated in September 2026, Australian pharmacies supplied 125 Category 1 Schedule 4 pure CBD products (>=98% cannabidiol) and 86 Category 2 CBD-dominant oils during the first six months of 2026 [12]. The CBD oil market size in Australia is expected to climb at a 13.2% annual rate over the 2026 to 2036 period as telehealth clinics streamline chronic pain and anxiety prescribing. Strict TGO 93 GMP import audits still favor certified suppliers.

Key takeaway: In Australia, expanding Authorised Prescriber telehealth networks and Schedule 4 pharmacy fulfillment are expected to drive sustained medicinal CBD oil volume.

Canada CBD Oil Market Outlook (2026 to 2036)

Federal licensing under the Cannabis Act and EU-GMP pharmaceutical export facilities set Canada apart from fragmented state-by-state U.S. hemp operations. In October 2026, Health Canada released its 2025 to 2026 Cannabis Inspection Data Summary together with updated ICH Q2(R2) analytical validation rules covering cannabinoid potency and impurity testing across licensed processors [13]. Canadian CBD oil industry valuation is forecast to advance at a 12.9% annual pace through 2036 as domestic licensed producers ship high-margin medical oils to Germany and Poland as well as Australia. Although April 2026 cuts to Veterans Affairs Canada reimbursement caps squeeze domestic clinic margins, producers are countering local price pressure with fast-acting emulsified drops and high-CBD softgels.

Key takeaway: In Canada, strict ICH Q2(R2) analytical validation and expanding EU-GMP medical oil exports are forecast to sustain long-term revenue expansion.

Germany CBD Oil Market Outlook (2026 to 2036)

Germany transformed its pharmacy market under the April 2024 Medical Cannabis Act (MedCanG) by taking medical cannabis off the Federal Narcotics List and allowing standard electronic prescriptions instead of special narcotic forms. In January 2026, a study from University Hospital Erlangen in the Journal of Cannabis Research tracked a 216% jump in German medical cannabis search interest to an index peak of 75.29 through December 2025 as telemedicine clinics connected patients with local pharmacies [14]. German CBD oil sector valuation is anticipated to grow at an 11.8% yearly clip through 2036 across community pharmacies and statutory health insurance pain pathways, while strict German Pharmacopoeia testing favors EU-GMP extractors.

Key takeaway: In Germany, non-narcotic e-prescription workflows under MedCanG and statutory GKV pharmacy reimbursement are anticipated to accelerate clinical CBD oil dispensing.

USA CBD Oil Market Outlook (2026 to 2036)

United States demand operates across a dual regulatory structure combining FDA-approved prescription anticonvulsant oral solutions with federally legal USDA organic hemp-derived wellness tinctures. In August 2026, CV Sciences reported second-quarter 2026 financial results noting that the U.S. Senate voted 61 to 32 to approve Continuing Resolution H.R. 6500, delaying restrictive federal hemp-cannabinoid provisions while preserving retail access for science-backed hemp extracts [15]. The CBD oil market value across the USA is predicted to rise at an 11.4% compound annual rate through 2036 across specialty pharmacies and natural-product grocers. While state potency caps on intoxicating hemp derivatives tighten compliance, vertically integrated extractors with GRAS-affirmed full-spectrum oils capture recurring retail shelf space.

Key takeaway: In the USA, federal legislative continuity under H.R. 6500 and expanding neurology pharmacy coverage are predicted to support steady multi-channel oil growth.

UK CBD Oil Market Outlook (2026 to 2036)

What sets the United Kingdom apart from continental European markets is the combination of Food Standards Agency (FSA) Novel Food Public List enforcement and private specialist clinic prescribing tracked by the UK Medical Cannabis Registry. A February 2026 systematic review and meta-analysis of 64 medicinal cannabis studies covering 43,847 patients published in Quality of Life Research found that 34% of global real-world clinical cohorts originated in the UK and documented significant health-related quality-of-life gains in chronic pain and anxiety [16]. British CBD oil market valuation is estimated to advance at an 11.2% annual rate through 2036. High FSA toxicological dossier costs and a 10-milligram daily OTC guidance ceiling favor validated isolate and broad-spectrum oil formulators.

Key takeaway: In the UK, private specialist registry prescribing and FSA Novel Food toxicological compliance are estimated to concentrate market share among validated oil suppliers.

Full report country CAGRs cover: North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa.

Who are the notable companies in the CBD oil market?

Jazz Pharmaceuticals plc, Charlotte's Web Holdings, Inc., Tilray Brands, Inc., Canopy Growth Corporation, Cronos Group Inc., Aurora Cannabis Inc., CV Sciences, Inc., and Lazarus Naturals are the notable companies in the CBD oil market.

FMI analysis shows that competition splits between prescription drug makers and international medical cannabis exporters as well as farm-to-bottle U.S. hemp wellness brands. Pharmaceutical leaders hold regulatory approvals and orphan-drug exclusivity for purified oral cannabidiol solutions in hospital neurology wards. Meanwhile, Canadian EU-GMP licensed producers export standardized medical cannabis oils to pharmacies across German and British pharmacies as well as Australia, whilst U.S. hemp specialists sell USDA-certified organic sublingual drops through natural grocery and online stores.

• Pharmaceutical & EU-GMP Medical Cannabinoid Leaders: Jazz Pharmaceuticals plc and Aurora Cannabis Inc. supply prescription oral cannabidiol solutions and EU-GMP pharmacy oil extracts across global neurology and pain pathways.
• Multi-National Medical & Wellness Cannabis Platforms: Tilray Brands, Inc. and Canopy Growth Corporation together with Cronos Group Inc. run multi-country GMP cultivation and oil extraction hubs serving medical pharmacies and wellness stores.
• Vertically Integrated Hemp & Nutraceutical Oil Specialists: Charlotte's Web Holdings, Inc. and CV Sciences, Inc. together with Lazarus Naturals formulate traceable full-spectrum and isolate hemp CBD tinctures for retail and direct-to-consumer buyers.

Competitive Benchmarking: CBD Oil Market

Table 8: Competitive Benchmarking for the CBD Oil Market (qualitative capability ratings), 2026

Company	Spectrum & Formulation Breadth	GMP & Clinical Validation Depth	Pharmacy / Retail Channel Access	Geographic Reach
Jazz Pharmaceuticals plc	Medium	High	High	High
Charlotte's Web Holdings, Inc.	High	High	High	Medium
Tilray Brands, Inc.	High	High	High	High
Canopy Growth Corporation	High	Medium	Medium	High
Cronos Group Inc.	Medium	Medium	Medium	Medium
Aurora Cannabis Inc.	High	High	High	High
CV Sciences, Inc.	High	High	Medium	Medium
Lazarus Naturals	High	Medium	Medium	Medium

Scoring basis: Capability tiers reflect product range across whole-plant distillate and pure isolate oils together with clinical trial or GRAS safety files. Pharmacy and geographic ratings reflect EU-GMP export licenses and hospital formulary listings as well as multi-country pharmacy distribution.

Key Developments in the CBD Oil Market

• Aurora Cannabis Inc. reported record fiscal 2026 global medical cannabis net revenue of CAD 288.6 million (up 18% year-over-year) in June 2026 and completed the CAD 26.5 million acquisition of EU-GMP manufacturer Safari Flower Company [17].
• Cronos Group Inc. announced second-quarter 2026 net revenue of USD 53.0 million (up 58% year-over-year) in August 2026 driven by strong PEACE NATURALS medical cannabis shipments across German and British clinics together with Israel [18].
• Tilray Brands, Inc. reported fiscal 2026 first-quarter net revenue of USD 209.5 million in October 2025, supported by USD 64.5 million in cannabis sales and USD 15.2 million in hemp wellness division turnover [19].

Key Players in the CBD Oil Market

Pharmaceutical & EU-GMP Medical Cannabinoid Leaders

• Jazz Pharmaceuticals plc
• Aurora Cannabis Inc.

Multi-National Medical & Wellness Cannabis Platforms

• Tilray Brands, Inc.
• Canopy Growth Corporation
• Cronos Group Inc.

Vertically Integrated Hemp & Nutraceutical Oil Specialists

• Charlotte's Web Holdings, Inc.
• CV Sciences, Inc.
• Lazarus Naturals

CBD Oil Market - Report Scope

Table 9: Report Scope for the CBD Oil Market (coverage fields and definitions), 2026 to 2036

Coverage field	Report scope
Market breakdown	Botanical Source; Spectrum Profile; End-Use Vertical; Extraction Technology; Distribution Channel
Quantitative Units	USD Billion
Market Definition	Includes commercial supplier revenue from industrial hemp-derived and medical cannabis-derived cannabidiol (CBD) oils, full-spectrum and broad-spectrum distillates, 99%+ CBD isolate in carrier oils, and finished pharmaceutical, nutraceutical, and topical CBD oil formulations. Category Scope Note: Excludes cold-pressed hemp seed culinary oil lacking phytocannabinoids, raw smokable cannabis flower, and high-THC recreational concentrates.
Regions Covered	North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa
Countries Covered	Brazil, Australia, Canada, Germany, USA, UK, and additional countries in the full report
Key Companies Covered	Jazz Pharmaceuticals plc, Charlotte's Web Holdings, Inc., Tilray Brands, Inc., Canopy Growth Corporation, Cronos Group Inc., Aurora Cannabis Inc., CV Sciences, Inc., Lazarus Naturals
Forecast Period	2026 to 2036
Approach	Primary and secondary research with top-down and bottom-up market triangulation.

CBD Oil Market - Research Methodology

Table 10: Research Methodology for the CBD Oil Market (research methods and approach), 2026 edition

Method	Approach
Primary Research	Structured interviews with supercritical CO2 extraction directors, hospital neurology pharmacists, EU-GMP medical cannabis exporters, and natural-product compliance officers to validate cannabinoid yield and pricing.
Secondary Research	Analysis of SEC and SEDAR+ corporate filings, USDA NASS National Hemp Reports, TGA and Health Canada regulatory registries, ANVISA RDC 327/2019 pharmacy records, and peer-reviewed PubMed clinical trials.
Market Sizing and Forecasting	Top-down pharmaceutical and nutraceutical cannabinoid expenditure models reconciled against bottom-up floral hemp biomass extraction tonnage and prescription patient registries from 2026 to 2036.
Country Forecasting Model	Econometric country projections weight national pharmacy reimbursement frameworks, specialist telemedical prescribing growth, and statutory THC compliance thresholds across six national jurisdictions.
Operational Benchmark Traceability	Biomass extraction and pharmacy spending indicators in Tables 2, 3, and 4 trace to USDA NASS acreage yields, ACS supercritical CO2 recovery benchmarks, and Epidiolex prescription revenue disclosures.
Data Triangulation and Validation	Demand estimates are cross-checked against licensed processor distillate output and pharmacy dispensing audits without double counting non-cannabinoid hemp seed oil or smokable flower.

CBD Oil Market by Segments

CBD Oil Market segmented by Botanical Source:

• Industrial Hemp-Derived CBD Oil
• Medical Cannabis-Derived CBD Oil

CBD Oil Market segmented by Spectrum Profile:

• Full-Spectrum & Broad-Spectrum Distillate
• 99%+ Pure Crystalline CBD Isolate in MCT Carrier Oil

CBD Oil Market segmented by End-Use Vertical:

• Pharmaceuticals
• Nutraceutical Sublingual Tinctures & Softgels
• Topical Balms, Skincare & Functional Beverages

CBD Oil Market segmented by Extraction Technology:

• Supercritical CO2 Extraction
• Cryogenic Ethanol Extraction
• Hydrocarbon & Lipid Infusion

CBD Oil Market segmented by Distribution Channel:

• Hospital & Retail Prescription Pharmacies
• D2C E-Commerce & Specialty Wellness
• Licensed Medical Dispensaries

CBD Oil Market by Region

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
• Western Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• [1] Pratama, R., Muhaimin, M., Khairinisa, M. A., & Chaerunisaa, A. Y. (2026, May 18). Adjunctive Cannabidiol for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis of Randomized Trials Across Syndromes, Formulations, and Dose Ranges. Therapeutics and Clinical Risk Management, 22, 601774 (PubMed PMID 42179430).
• [2] National Agricultural Statistics Service (NASS). (2026, April 16). National Hemp Report. United States Department of Agriculture (USDA).
• [3] Smith, R. T., Dahlgren, M. K., Sagar, K. A., Kosereisoglu, D., & Gruber, S. A. (2025, August 1). Clinical and Cognitive Improvement Following Treatment with a Hemp-Derived, Full-Spectrum, High-Cannabidiol Product in Patients with Anxiety: An Open-Label Pilot Study. Biomedicines, 13(8), 1874 (PubMed PMID 40868129).
• [4] Brstilo, L., Valenzuela, G. R., Ibarra, M., Guido, P. C., Bressan, I., et al. (2025, January 13). Population pharmacokinetics of cannabidiol and the impact of food and formulation on systemic exposure in children with drug-resistant developmental and epileptic encephalopathies. Epilepsia, 66(4), 1143-1154 (PubMed PMID 39804155).
• [5] Jazz Pharmaceuticals plc. (2026, February 24). Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results. Jazz Pharmaceuticals Investor Relations.
• [6] Calmanti, R., Selva, M., & Perosa, A. (2025, February 17). From Hemp to CBD Crystals: A Scaled-Up Procedure for the Selective Extraction, Isolation, and Purification of Cannabidiol. ACS Agricultural Science & Technology, 5(3), 346-354 (PubMed PMID 40115243).
• [7] Jazz Pharmaceuticals plc. (2026, August 3). Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results. Jazz Pharmaceuticals Investor Relations.
• [8] Dubnika, A., Jurgelane, I., Grava-Ceplite, A., Tornaci, S., Porfiryeva, N. N., et al. (2025, October 10). Exploring the therapeutic potential of cannabidiol in soft tissue wound healing: Delivery strategies and anti-inflammatory pathways. Acta Pharmaceutica Sinica B, 16(4), 2174-2195 (PubMed PMID 42039297).
• [9] Białoń, M., Kędziora, M., & Starowicz, K. (2026, February 17). Cannabidiol in Neurology: Current Insights and Translational Perspectives. Pharmaceuticals, 19(2), 330 (PubMed PMID 41754870).
• [10] Paczkowska-Walendowska, M., Trzaskoma, P., Dziopa, A., Moeini, A., Soczawa, M., Krasiński, Z., & Cielecka-Piontek, J. (2025, October 29). Innovative Strategies to Enhance the Bioavailability of Cannabidiol: Nanotechnology and Advanced Delivery Systems. Pharmaceuticals, 18(11), 1637 (PubMed PMID 41304881).
• [11] Gallassi, A. D., de Oliveira, A. W. C., Mendes, N. S., Filev, R., & Nakano, E. Y. (2025, February 22). Evaluation of cannabidiol-based products in Brazil: how can current regulations influence their labeling quality?. Journal of Cannabis Research, 7, 12 (PubMed PMID 39987154).
• [12] Therapeutic Goods Administration (TGA). (2026, September 17). Medicinal cannabis product list. Australian Government Department of Health, Disability and Ageing.
• [13] Health Canada. (2026, October 13). Updates for cannabis and industrial hemp. Government of Canada.
• [14] Kirchberger, M. C. (2026, January 27). Post-legalization rise in German medical cannabis interest: evidence from Google trends as surrogate marker. Journal of Cannabis Research, 8, 15 (PubMed PMID 41593723).
• [15] CV Sciences, Inc. (2026, August 13). CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results. CV Sciences Investor Relations.
• [16] Tait, M.-A., Acret, L., Costa, D. S. J., Campbell, R., White, K., & Rutherford, C. (2026, February 1). Health-related quality of life in patients receiving medicinal cannabis: systematic review and meta-analysis of primary research findings 2015 to 2025. Quality of Life Research, 35(3), 56 (PubMed PMID 41621036).
• [17] Aurora Cannabis Inc. (2026, June 11). Aurora Cannabis Announces Full Year and Fiscal 2026 Fourth Quarter Results with Record Annual Revenue and Adjusted EBITDA. Aurora Cannabis Investor Relations.
• [18] Cronos Group Inc. (2026, August 6). Cronos Group Reports 2026 Second Quarter Results. Cronos Group Investor Relations.
• [19] Tilray Brands, Inc. (2025, October 9). Tilray Brands Reports Strong First Quarter Fiscal 2026 Results. Tilray Brands Investor Relations.
• [20] Charlotte's Web Holdings, Inc. (2025, August 13). Charlotte's Web Reports Year-Over-Year Growth For Q2 2025. Charlotte's Web Investor Relations.
• [21] Lazarus Naturals. (2026, May 6). Full Spectrum High Potency Tincture | CBD. Etz Hayim Holdings, SPC - Lazarus Naturals.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• How large is the CBD oil market in 2026 and what is forecast for 2036?
• Which clinical neurology and regulatory pressures support demand for CBD oils?
• Why does Industrial Hemp-Derived CBD Oil lead the botanical source category?
• Why does Full-Spectrum & Broad-Spectrum Distillate lead the spectrum profile category globally?
• How do growth rates differ across Brazil, Australia, Canada, Germany, the USA, and the UK?
• Which leading companies manufacture pharmaceutical and nutraceutical CBD oils today?
• What limits adoption or dose escalation in the CBD oil market?
• What should pharmacy and brand buyers evaluate before purchasing CBD oil?